What is Zacks Research’s Forecast for Exelixis Q1 Earnings?

Exelixis, Inc. (NASDAQ:EXEL) – Investment analysts at Zacks Research upped their Q1 2026 earnings estimates for Exelixis in a research report issued on Friday, February 6th. Zacks Research analyst Team now expects that the biotechnology company will post earnings per share of $0.65 for the quarter, up from their previous forecast of $0.61. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Exelixis’ current full-year earnings is $2.04 per share. Zacks Research also issued estimates for Exelixis’ Q2 2026 earnings at $0.68 EPS, FY2026 earnings at $2.91 EPS, Q1 2027 earnings at $0.80 EPS, Q3 2027 earnings at $0.97 EPS, Q4 2027 earnings at $1.12 EPS and FY2027 earnings at $3.84 EPS.

Other equities analysts also recently issued research reports about the company. Truist Financial set a $51.00 target price on Exelixis in a research report on Wednesday, January 14th. Royal Bank Of Canada reissued a “sector perform” rating and issued a $45.00 price objective on shares of Exelixis in a research note on Tuesday, October 21st. Wells Fargo & Company decreased their price objective on Exelixis from $36.00 to $30.00 and set an “equal weight” rating on the stock in a report on Tuesday, October 21st. HC Wainwright reaffirmed a “buy” rating and set a $52.00 target price on shares of Exelixis in a report on Tuesday, February 3rd. Finally, Leerink Partners upgraded shares of Exelixis from a “market perform” rating to an “outperform” rating and set a $48.00 target price for the company in a research report on Tuesday, October 21st. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Exelixis currently has a consensus rating of “Hold” and an average target price of $46.16.

Exelixis Trading Up 3.6%

Shares of Exelixis stock opened at $43.90 on Monday. Exelixis has a twelve month low of $32.38 and a twelve month high of $49.62. The firm has a market capitalization of $11.77 billion, a PE ratio of 18.52, a P/E/G ratio of 0.74 and a beta of 0.42. The firm’s 50-day moving average price is $43.69 and its 200 day moving average price is $40.95.

Institutional Investors Weigh In On Exelixis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Truist Financial Corp lifted its position in Exelixis by 1.1% in the second quarter. Truist Financial Corp now owns 22,292 shares of the biotechnology company’s stock valued at $983,000 after buying an additional 250 shares during the last quarter. Police & Firemen s Retirement System of New Jersey raised its stake in shares of Exelixis by 0.3% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 102,581 shares of the biotechnology company’s stock valued at $4,521,000 after acquiring an additional 274 shares during the period. Richardson Financial Services Inc. raised its stake in shares of Exelixis by 95.1% in the 3rd quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 292 shares during the period. RHS Financial LLC lifted its holdings in shares of Exelixis by 2.4% in the 4th quarter. RHS Financial LLC now owns 12,619 shares of the biotechnology company’s stock worth $553,000 after acquiring an additional 293 shares during the last quarter. Finally, Cim LLC boosted its position in shares of Exelixis by 0.9% during the 3rd quarter. Cim LLC now owns 35,397 shares of the biotechnology company’s stock worth $1,462,000 after purchasing an additional 305 shares during the period. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Insider Activity

In other Exelixis news, Director Mary C. Beckerle sold 24,622 shares of the business’s stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $41.93, for a total value of $1,032,400.46. Following the transaction, the director directly owned 21,380 shares in the company, valued at $896,463.40. The trade was a 53.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Dana Aftab sold 48,383 shares of the stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $42.50, for a total transaction of $2,056,277.50. Following the completion of the sale, the executive vice president directly owned 664,778 shares of the company’s stock, valued at approximately $28,253,065. This trade represents a 6.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 245,235 shares of company stock valued at $10,490,600 over the last three months. 2.82% of the stock is currently owned by company insiders.

Key Exelixis News

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Zacks Research upgraded Exelixis from a “hold” to a “strong‑buy,” signaling increased analyst conviction that the company’s growth story is improving. Read More.
• Positive Sentiment: Zacks issued broad upward revisions to Exelixis’ earnings outlook — raising FY2026 to $2.76 from $2.34 and FY2027 to $3.65 (previously $3.30), and lifting several quarterly estimates (e.g., Q1‑Q4 2026 and Q1‑Q4 2027). These higher forward EPS forecasts support a re‑rating and provide a clearer path to earnings growth. Read More.
• Positive Sentiment: Zacks published a bullish write‑up, “3 Reasons Why Growth Investors Shouldn’t Overlook Exelixis,” highlighting growth attributes that could help EXEL outperform — a narrative that can attract growth‑oriented buyers. Read More.
• Positive Sentiment: HC Wainwright reaffirmed its “Buy” rating on EXEL, providing additional sell‑side support that may encourage institutional interest. Read More.
• Neutral Sentiment: Note that Zacks’ upgraded forecasts exceed the current broader consensus (the entries cite a consensus near $2.04 for the current year). The market may await confirmation from Exelixis’ upcoming results/sales trends before other analysts materially follow, which could create short‑term volatility. Read More.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.